ArticleTranslational cancer research2026
Tumor-intrinsic B4GALNT3 expression drives a protective immune microenvironment in endometriosis-associated ovarian cancer.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although endometriosis-associated ovarian cancer (EAOC) is considered a separate clinical entity, no specific prognostic biomarkers aid in its management. This has, therefore, been among the factors hindering the development of tailored treatments. We aim to develop a robust, histotype-aware biomarker for EAOC through an integrative computational approach to explain its association with the tumor immune microenvironment. Methods: A multi-stage bioinformatics approach using multiple independent Gene Expression Omnibus (GEO) cohorts was employed. We extracted consensus differentially expressed genes (DEGs) from three discovery datasets (EAOC Results: From our analysis, we identified 75 consensus DEGs distilled into five hub genes. Among these, B4GALNT3 was the key candidate. While the pan-ovarian cancer meta-analysis showed a non-significant protective trend, we confirmed in our EAOC-enriched validation cohort that high B4GALNT3 expression was significantly associated with improved overall survival [hazard ratio (HR) =0.350, P=0.04]. It showed robust diagnostic potential with an overall area under the curve (AUC) of 0.962 [95% confidence interval (CI): 0.923-0.993] in leave-one-dataset-out cross-validation among discovery datasets. Immune deconvolution revealed that B4GALNT3 expression correlated with an anti-tumor microenvironment composed of increased levels of plasma B cells, memory B cells, and activated dendritic cells, with decreased regulatory T cells and M2 macrophages. Finally, scRNA-seq analysis confirmed that B4GALNT3 was intrinsically highly expressed in malignant and epithelial cells, with low expression in immune lineages. Conclusions: B4GALNT3 is a novel, subtype-specific protective biomarker in EAOC. Our findings support a mechanism by which tumor-cell-intrinsic expression of B4GALNT3 drives protection from immune microenvironments. This work identifies B4GALNT3 as a promising prognostic factor and potential target for further mechanistic studies and protein-level validation in EAOC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.